Robert C, Grob JJ, Stroyakovskiy D, et al. - Pooled extended-survival data from two trials including formerly untreated 563 patients who had received BRAF inhibitor dabrafenib plus MEK inhibitor trametinib in the COMBI-d and COMBI-v trials were investigated by the experts in order to determine, in metastatic melanoma, five-year outcomes with dabrafenib plus trametinib. Various baseline factors like performance status, age, gender, number of organ sites with metastasis, and lactate dehydrogenase level were significantly correlated with both progression-free survival and overall survival. In 109 patients, a complete response occurred and was related to an enhanced long-term outcome, with an overall survival rate of 71% at 5 years. Hence, first-line treatment with dabrafenib plus trametinib resulted in long-term advantage in nearly one third of the patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.